Assessing an Acquisition’s Market Access Potential

Leah Hoffmann

A multi-million-dollar pharmaceutical company was in talks to acquire an orphan drug manufacturer with a pipeline asset that was about to launch in Europe. The company’s corporate development team was focused on the deal’s financials, but they lacked the expertise to assess the access potential of the new drug. Looking for highly targeted due diligence support, they turned to Business Talent Group.

We engaged a former Deloitte consultant who’d held senior market access roles at top global pharma companies. He investigated the target’s launch plans and timing for the new asset, along with early pricing and reimbursement estimates. He also evaluated the deal’s implications to the company’s broader commercial strategy and how post-integration staffing could affect the asset’s launch.

After concluding that the target lacked some of the resources it would need to conduct successful market access negotiations throughout the region, Business Talent Group’s consultant put together a detailed staffing plan that enabled the company to confidently—and capably—move forward with the acquisition.

 

Previous Article
IDN Engagement Strategies
IDN Engagement Strategies

A biopharma company was building a value-based partnership program to deepen customer engagement and ensure...

Next Article
Rethinking Health Analytics Strategies
Rethinking Health Analytics Strategies

A global biopharma company was struggling to manage its growing pipeline of health analytics initiatives. H...

×

Talk with BTG to learn more about our on-demand talent.

First Name
Last Name
Company
Country
I would like to receive the latest expert insights and news from Business Talent Group.
By registering, you agree to the processing of your personal data by Business Talent Group as described in the Privacy Statement.
View our Privacy Policy and Cookie Policy
Thank you! We will be in touch shortly.
Error - something went wrong!